Daniel V LaBarbera
Overview
Explore the profile of Daniel V LaBarbera including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
957
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Esquer H, Zhou Q, LaBarbera D
Cells
. 2025 Mar;
14(5).
PMID: 40072047
The second and third most frequently diagnosed cancers worldwide are breast (2.3 million new cases) and colorectal (1.9 million new cases), respectively. Although advances in cancer therapies and early detection...
2.
Sala R, Esquer H, Kellett T, Clune S, Awolade P, Pike L, et al.
Int J Mol Sci
. 2024 Dec;
25(23).
PMID: 39684869
Colorectal cancer (CRC) is one of the most prevalent and deadly forms of cancer. It is universally treated with a combination of the DNA damaging chemotherapy drugs irinotecan, 5-Fluorouracil (5-FU),...
3.
Sala R, Esquer H, Kellett T, Kearns J, Awolade P, Zhou Q, et al.
Int J Mol Sci
. 2024 Aug;
25(16).
PMID: 39201277
The Chromodomain helicase DNA-binding protein 1-like (CHD1L) is a nucleosome remodeling enzyme, which plays a key role in chromatin relaxation during the DNA damage response. Genome editing has shown that...
4.
Chatterji P, Xing G, Furst L, Dave K, Zhou Q, LaBarbera D, et al.
bioRxiv
. 2024 May;
PMID: 38746359
Ferroptosis is a cell death mechanism that has attracted significant attention as a potential basis for the development of new cancer therapies. Validation of ferroptosis biology in species commonly used...
5.
Clune S, Awolade P, Zhou Q, Esquer H, Matter B, Kearns J, et al.
Biomed Pharmacother
. 2023 Dec;
170:116037.
PMID: 38128184
Chromodomain helicase DNA-binding protein 1 like (CHD1L) is an oncogene that promotes tumor progression, metastasis, and multidrug resistance. CHD1L expression is indicative of poor outcomes and low survival in cancer...
6.
Kellett T, Noor R, Zhou Q, Esquer H, Sala R, Stojanovic P, et al.
SLAS Discov
. 2023 Oct;
28(8):394-401.
PMID: 37844763
PARP1/2 inhibitors (PARPi) are effective clinically used drugs for the treatment of cancers with BRCA deficiencies. PARPi have had limited success and applicability beyond BRCA deficient cancers, and their effect...
7.
Agarwal N, Zhou Q, Arya D, Rinaldetti S, Duex J, LaBarbera D, et al.
Int J Mol Sci
. 2022 Sep;
23(18).
PMID: 36142729
Mutations in the promoter of the human Telomerase Reverse Transcriptase (hTERT) gene are common and associated with its elevated expression in bladder cancer, melanoma, and glioblastoma. Though these mutations and...
8.
Rinaldetti S, Zhou Q, Abbott J, de Jong F, Esquer H, Costello J, et al.
Int J Mol Sci
. 2022 Sep;
23(18).
PMID: 36142576
Molecular subtypes of muscle-invasive bladder cancer (MIBC) display differential survival and drug sensitivities in clinical trials. To date, they have not been used as a paradigm for phenotypic drug discovery....
9.
Prutton K, Marentette J, Leifheit B, Esquer H, LaBarbera D, Anderson C, et al.
Free Radic Biol Med
. 2022 May;
186:32-42.
PMID: 35537597
The ubiquity of cognitive deficits and early onset Alzheimer's disease in Down syndrome (DS) has focused much DS iPSC-based research on neuron degeneration and regeneration. Despite reports of elevated oxidative...
10.
Prigaro B, Esquer H, Zhou Q, Pike L, Awolade P, Lai X, et al.
J Med Chem
. 2022 Feb;
65(5):3943-3961.
PMID: 35192363
Chromodomain helicase DNA-binding protein 1 like (CHD1L) is an oncogene implicated in tumor progression, multidrug resistance, and metastasis in many types of cancer. In this article, we described the optimization...